Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Novartis Buys Avrobio Gene Therapy for $88 Million | Contract Pharma

What are you searching for?

Sign in
Breaking News

Novartis Buys Avrobio Gene Therapy for $88 Million

Purchases stem cell gene therapy program for cystinosis.

By: Rachel Klemovitch

Assistant Editor

Novartis has made a deal to buy Avrobio’s investigational hematopoietic stem cell (HSC) gene therapy program focusing on cystinosis treatment of cystinosis, a rare genetic disease. This was a $87.5 million cash deal expected to extend Avrobio’s cash runway into the fourth quarter of 2024.
 
Avrobio is a leading company in clinical-stage gene therapy and will continue to have full rights to its HSC gene therapy portfolio. This first-in-class HSC gene therapy focuses on lifetime generic diseases such as Hunter syndrome, Gaucher disease type 1 and type 3, and Pompe disease. 
 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics